Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(12 sites)

China

Anhui Provincial Cancer Hospital, Hefei, Anhui

The First People's Hospital of Foshan, Foshan, Guangdong

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong

The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong

The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

Henan Cancer Hospital, Zhengzhou, Henan

The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality

West China Hospital of Sichuan University, Chengdu, Sichuan

The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan

The First Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, Zhejiang